Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy

被引:125
|
作者
Rapoport, Bernardo L. [1 ,2 ]
Anderson, Ronald [1 ,3 ]
机构
[1] Univ Pretoria, Dept Immunol, Fac Hlth Sci, ZA-0001 Pretoria, South Africa
[2] Med Oncol Ctr Rosebank, ZA-2196 Johannesburg, South Africa
[3] Univ Pretoria, Inst Cellular & Mol Med, Fac Hlth Sci, ZA-0001 Pretoria, South Africa
来源
关键词
calreticulin; damage-associated molecular patterns (DAMPs); dendritic cells; high mobility group box1; immunogenic cell death; immune checkpoint inhibitors; monoclonal antibodies; type I interferons; ANTITUMOR IMMUNITY; DNA-DAMAGE; T-CELLS; CALRETICULIN EXPOSURE; CROSS-PRESENTATION; DENDRITIC CELLS; LIGAND; TUMOR; INFLAMMATION; MECHANISMS;
D O I
10.3390/ijms20040959
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunogenic cell death (ICD), which is triggered by exposure of tumor cells to a limited range of anticancer drugs, radiotherapy, and photodynamic therapy, represents a recent innovation in the revitalized and burgeoning field of oncoimmunnotherapy. ICD results in the cellular redistribution and extracellular release of damage-associated molecular patterns (DAMPs), which have the potential to activate and restore tumor-targeted immune responses. Although a convincing body of evidence exists with respect to the antitumor efficacy of ICD in various experimental systems, especially murine models of experimental anticancer immunotherapy, evidence for the existence of ICD in the clinical setting is less compelling. Following overviews of hallmark developments, which have sparked the revival of interest in the field of oncoimmunotherapy, types of tumor cell death and the various DAMPs most prominently involved in the activation of antitumor immune responses, the remainder of this review is focused on strategies which may potentiate ICD in the clinical setting. These include identification of tumor- and host-related factors predictive of the efficacy of ICD, the clinical utility of combinatorial immunotherapeutic strategies, novel small molecule inducers of ICD, novel and repurposed small molecule immunostimulants, as well as the critical requirement for validated biomarkers in predicting the efficacy of ICD.
引用
收藏
页数:27
相关论文
共 50 条
  • [21] Immunogenic versus Non-Immunogenic Cell Death in Cancer
    Garg, A.
    Vandenberk, L.
    Fang, S.
    De Witte, P.
    Salven, P.
    Agostinis, P.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S60 - S60
  • [22] Herbal polysaccharide-based carrier enhances immunogenic cell death in cancer chemotherapy
    Tao, Shengchang
    Song, Yuchen
    Liu, Liuyi
    Ma, Wenwen
    Zhou, Benjie
    Hu, Fang
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 302
  • [23] Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
    Yang, Heng
    Ma, Yuting
    Chen, Guo
    Zhou, Heng
    Yamazaki, Takahiro
    Klein, Christophe
    Pietrocola, Federico
    Vacchelli, Erika
    Souquere, Sylvie
    Sauvat, Allan
    Zitvogel, Laurence
    Kepp, Oliver
    Kroemer, Guido
    ONCOIMMUNOLOGY, 2016, 5 (06):
  • [24] Silibinin induces immunogenic cell death in cancer cells and enhances the induced immunogenicity by chemotherapy
    Jafari, Sevda
    Heydarian, Saba
    Lai, Raymond
    Aghdam, Elnaz Mehdizadeh
    Molavi, Ommoleila
    BIOIMPACTS, 2023, 13 (01) : 51 - 61
  • [25] Engineering Calreticulin-Targeting Monobodies to Detect Immunogenic Cell Death in Cancer Chemotherapy
    Zhang, Ying
    Thangam, Ramar
    You, Sung-Hwan
    Sultonova, Rukhsora D.
    Venu, Akhil
    Min, Jung-Joon
    Hong, Yeongjin
    CANCERS, 2021, 13 (11)
  • [26] Hafnium oxide nanoparticles with radiotherapy induce immunogenic cell death
    Marill, Julie
    Mohamed, Naeemunnisa
    Darmon, Audrey
    Levy, Laurent
    Borghi, Elsa
    Pottier, Agnes
    Paris, Sebastien
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [27] Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma
    Aoto, Keita
    Mimura, Kousaku
    Okayama, Hirokazu
    Saito, Motonobu
    Chida, Shun
    Noda, Masaru
    Nakajima, Takahiro
    Saito, Katsuharu
    Abe, Noriko
    Ohki, Shinji
    Ohtake, Tohru
    Takenoshita, Seiichi
    Kono, Koji
    ONCOLOGY REPORTS, 2018, 39 (01) : 151 - 159
  • [28] Immunogenic cell stress and death in the treatment of cancer
    Pan, Hui
    Liu, Peng
    Zhao, Liwei
    Pan, Yuhong
    Mao, Misha
    Kroemer, Guido
    Kepp, Oliver
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2024, 156 : 11 - 21
  • [29] Immunogenic effects of chemotherapy-induced tumor cell death
    Wang, Yi-Jun
    Fletcher, Rochelle
    Yu, Jian
    Zhang, Lin
    GENES & DISEASES, 2018, 5 (03) : 194 - 203
  • [30] Immunogenic cell death in cancer and infectious disease
    Galluzzi, Lorenzo
    Buque, Aitziber
    Kepp, Oliver
    Zitvogel, Laurence
    Kroemer, Guido
    NATURE REVIEWS IMMUNOLOGY, 2017, 17 (02) : 97 - 111